BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 29284465)

  • 1. Acupuncture for patients with mild to moderate Alzheimer's disease: a randomized controlled trial.
    Jia Y; Zhang X; Yu J; Han J; Yu T; Shi J; Zhao L; Nie K
    BMC Complement Altern Med; 2017 Dec; 17(1):556. PubMed ID: 29284465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
    Rogers SL; Doody RS; Mohs RC; Friedhoff LT
    Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of donepezil in Alzheimer's disease - results from a multinational trial.
    Burns A; Rossor M; Hecker J; Gauthier S; Petit H; Möller HJ; Rogers SL; Friedhoff LT
    Dement Geriatr Cogn Disord; 1999; 10(3):237-44. PubMed ID: 10325453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
    Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
    Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.
    Doody RS; Corey-Bloom J; Zhang R; Li H; Ieni J; Schindler R
    Drugs Aging; 2008; 25(2):163-74. PubMed ID: 18257603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial.
    Xiao S; Wang T; Ma X; Qin Y; Li X; Zhao Z; Liu X; Wang X; Xie H; Jiang Q; Sun L; Luo B; Shang L; Chen W; Bai Y; Tang M; He M; Wu L; Ma Q; Hou D; He J
    Age Ageing; 2017 Sep; 46(5):767-773. PubMed ID: 28419192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.
    Rogers SL; Farlow MR; Doody RS; Mohs R; Friedhoff LT
    Neurology; 1998 Jan; 50(1):136-45. PubMed ID: 9443470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil.
    Alvarez XA; Cacabelos R; Sampedro C; Couceiro V; Aleixandre M; Vargas M; Linares C; Granizo E; García-Fantini M; Baurecht W; Doppler E; Moessler H
    Curr Alzheimer Res; 2011 Aug; 8(5):583-91. PubMed ID: 21679156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical observation on treatment of Alzheimer's disease with Sun's scalp-abdominal acupuncture combined with donepezil hydrochloride.
    Zhang SQ; Ma S; Yang TS; Zhang M
    Zhen Ci Yan Jiu; 2024 May; 49(5):506-511. PubMed ID: 38764122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two galantamine titration regimens in patients switched from donepezil.
    Engedal K; Davis B; Richarz U; Han J; Schäuble B; Andreasen N
    Acta Neurol Scand; 2012 Jul; 126(1):37-44. PubMed ID: 21992111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.
    Dubois B; Tolosa E; Katzenschlager R; Emre M; Lees AJ; Schumann G; Pourcher E; Gray J; Thomas G; Swartz J; Hsu T; Moline ML
    Mov Disord; 2012 Sep; 27(10):1230-8. PubMed ID: 22915447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donepezil Combined with DL-3-n-Butylphthalide Delays Cognitive Decline in Patients with Mild to Moderate Alzheimer's Disease: A Multicenter, Prospective Cohort Study.
    Wang J; Guo X; Lu W; Liu J; Zhang H; Quan Q; Su H; Ma L; Gao F; Qu Q
    J Alzheimers Dis; 2021; 80(2):673-681. PubMed ID: 33579850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients.
    Zhang N; Wei C; Du H; Shi FD; Cheng Y
    Dement Geriatr Cogn Disord; 2015; 40(1-2):85-93. PubMed ID: 26066622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
    Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial.
    Rockwood K; Fay S; Gorman M; Carver D; Graham JE
    BMC Neurol; 2007 Aug; 7():26. PubMed ID: 17760991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of electroacupuncture combined with donepezil on cognitive function in Alzheimer's disease patients: study protocol for a randomized controlled trial.
    Peng W; Zhou J; Xu M; Feng Q; Bin L; Liu Z
    Trials; 2017 Jul; 18(1):301. PubMed ID: 28673322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donepezil combined with natural hirudin improves the clinical symptoms of patients with mild-to-moderate Alzheimer's disease: a 20-week open-label pilot study.
    Li DQ; Zhou YP; Yang H
    Int J Med Sci; 2012; 9(3):248-55. PubMed ID: 22606044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.
    Amenta F; Carotenuto A; Fasanaro AM; Rea R; Traini E
    J Neurol Sci; 2012 Nov; 322(1-2):96-101. PubMed ID: 22959283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation.
    Kudoh C; Arita R; Honda M; Kishi T; Komatsu Y; Asou H; Mimura M
    Psychogeriatrics; 2016 Mar; 16(2):85-92. PubMed ID: 25918972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.